Biotech · Public company · Austin, TX, US
XBiotech Inc.
Ticker XBIT · SEC CIK 0001626878
Track this companyFree. Adds XBiotech Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials50 recruiting or active
Pipeline programs11From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availableNo recent cash burn filed
Pipeline11
- 514G3 (10 mg/kg) plus standard IV antibiotic treatmentPhase 2 · Staphylococcus Aureus BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- 514G3 (2 mg/kg) plus standard IV antibiotic treatmentPhase 2 · Staphylococcus Aureus BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- 514G3 (40 mg/kg) plus standard IV antibiotic treatmentPhase 2 · Staphylococcus Aureus BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase IIPhase 2 · Staphylococcus Aureus BacteremiaClinicalTrials.gov · fetched Nov 12, 2026
- NatrunixPhase 2 · Rheumatoid ArthritisClinicalTrials.gov · fetched Nov 12, 2026
- Phase I: XB2001 1000 mgPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Phase I: XB2001 250 mgPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Phase I: XB2001 500 mgPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- Phase II: XB2001 1000 mgPhase 2 · Pancreatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- HutrukinPhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
- NatrunixPhase 1 · PharmacokineticsClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisPHASE2 · COMPLETED · started Aug 8, 2023ClinicalTrials.gov NCT05363891 · fetched Nov 12, 2026
- Hutrukin to Analyze Safety and PK in Healthy VolunteersPHASE1 · COMPLETED · started Apr 10, 2023ClinicalTrials.gov NCT05098080 · fetched Nov 12, 2026
- Safety and Pharmacokinetics (PK) Study of Natrunix in Healthy VolunteersPHASE1 · COMPLETED · started Jan 19, 2022ClinicalTrials.gov NCT05099510 · fetched Nov 12, 2026
- XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic CancerPHASE1_PHASE2 · COMPLETED · started May 27, 2021ClinicalTrials.gov NCT04825288 · fetched Nov 12, 2026
- Safety & Efficacy of True Human Antibody, 514G3, in Staphylococcus Aureus Bacteremia Hospitalized Subjects.PHASE1_PHASE2 · COMPLETED · started May 1, 2015ClinicalTrials.gov NCT02357966 · fetched Nov 12, 2026
SEC filings12
- 8-K · FORM 8-KSEC EDGAR · filed Oct 26, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 13, 2026 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed May 14, 2026 · fetched Nov 12, 2026
- 10-K/A · FORM 10-K/ASEC EDGAR · filed Apr 29, 2026 · fetched Nov 12, 2026
- 10-K · FORM 10-KSEC EDGAR · filed Mar 13, 2026 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Dec 9, 2025 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Nov 12, 2025 · fetched Nov 12, 2026
- 8-K/A · FORM 8-K/ASEC EDGAR · filed Oct 15, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Oct 3, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Sep 2, 2025 · fetched Nov 12, 2026
- 10-Q · FORM 10-QSEC EDGAR · filed Aug 13, 2025 · fetched Nov 12, 2026
- 8-K · FORM 8-KSEC EDGAR · filed Jun 24, 2025 · fetched Nov 12, 2026